Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST)
C. M. O'Connor*, W. A. Gattis, B. F. Uretsky, Jr Adams K.F., S. E. McNulty, S. H. Grossman, W. J. McKenna, F. Zannad, K. Swedberg, M. Gheorghiade, R. M. Califf
Dive into the research topics of 'Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST)'. Together they form a unique fingerprint.